Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KICKSTART: Tomivosertib + Pembrolizumab in NSCLC
NCT04622007Phase 2Active, not recruiting
- Sponsor
- eFFECTOR Therapeutics
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of tomivosertib in non-small cell lung cancer (NSCLC), sponsored by eFFECTOR Therapeutics. Started Jun 2021; status: active, not recruiting.
02
Drugs
tomivosertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04622007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622007.